Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Y. Kito,K. Yamazaki, H. Shoji,T. Yamada,T. Tsushima,S. Mitani, K. Shiraishi,H. Yasui,H. Hara,K. Shimozaki,T. Esaki, H. Shimokawa,S. Kajiura,T. Masuishi,E. Baba, K. Yoshimura,H. Kawakami,S. Hironaka,K. MuroAnnals of Oncology（2022）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
